What is the optimum prophylaxis against gastrointestinal haemorrhage for patients undergoing adult cardiac surgery: Histamine receptor antagonists, or proton-pump inhibitors?

Interactive Cardiovascular and Thoracic Surgery

Volumn 16, Issue 3, 2013, Pages 356-360

  Patel, Akshay J ^a   Som, Robin ^b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Cardiac surgery; Gastrointestinal; Haemorrhage; Histamine type 2 receptor antagonist; Prophylaxis; Proton pump inhibitor

Indexed keywords

ACETYLSALICYLIC ACID; ANTACID AGENT; ANTIHISTAMINIC AGENT; C REACTIVE PROTEIN; CIMETIDINE; HISTAMINE H2 RECEPTOR AGONIST; INTERLEUKIN 6; INTERLEUKIN 8; OMEPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE; WARFARIN;

ADULT; ARTICLE; CLINICAL PROTOCOL; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DIGESTIVE SYSTEM ULCER; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART SURGERY; HELICOBACTER INFECTION; HOSPITAL INFECTION; HUMAN; INFECTION SENSITIVITY; MAJOR CLINICAL STUDY; MALE; OPEN HEART SURGERY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; RISK REDUCTION; STOMACH ACID;

AGED; BENCHMARKING; CARDIAC SURGICAL PROCEDURES; CHI-SQUARE DISTRIBUTION; EVIDENCE-BASED MEDICINE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HISTAMINE H2 ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84874307324     PISSN: 15699293     EISSN: 15699285     Source Type: Journal    
DOI: 10.1093/icvts/ivs483     Document Type: Article

References (17)

1. Dunning J, Prendergast B, Mackway-Jones K. Towards evidence-based medicine in cardiothoracic surgery: best BETS. Interact CardioVasc Thorac Surg 2003;2:405-9.
2. Shin JS, Abah U. Is routine stress ulcer prophylaxis of benefit for patients undergoing cardiac surgery? Interact CardioVasc Thorac Surg 2012;14:622-8.
3. Fan H, Zheng Z, Feng W, Wang W, Song Y, Lin Y et al. Risk factors and prevention of upper gastroinestinal haemorrhage after a coronary artery bypass grafting operation. Surg Today 2010;40:931-5.
4. Gon S, Irie Y, Takahashi M. Effects of rabeprazole or famotidine during cardiac surgery on perioperative gastric and esophageal pH readings. Jpn J Thorac Cardiovasc Surg 2006;54:278-84.
5. Hata M, Shiono M, Sekino H, Furukawa H, Sezai A, Iida M et al. Prospective randomised trial for optimal prophylactic treatment of the upper gastrointestinal complications after open heart surgery. Circ J 2005;69:331-4.
6. Johnston G, Vitikainen K, Knight R, Annest L, Garcia C. Changing perspective on gastrointestinal complications in patients undergoing cardiac surgery. Am J Surg 1992;163:525-9.
7. Katoh J, Tsuchiya K, Osawa H, Sato W, Matsumura G, Iida Y et al. Cimetidine reduces impairment of cellular immunity after cardiac operations with cardiopulmonary bypass. J Thorac Cardiovasc Surg 1998;116: 312-8.
8. Rosen HR, Vlahakes GJ, Rattner DW. Fulminant peptic ulcer disease in cardiac surgical patients: pathogenesis, prevention, and management. Crit Care Med 1992;20:354-9.
9. Stchepinsky OA, Theodose YV, Huisman JP, Gaultier YM, Maas HE. Prevention of gastrointestinal bleeding after a cardiac operation. Ann Thorac Surg 1998;66:296-310.
10. Tayama E, Hayashida N, Fukunaga S, Tayama K, Takaseya T, Hiratsuka R et al. High-dose cimetidine reduces proinflammatory reaction after cardiac surgery with cardiopulmonary bypass. Ann Thorac Surg 2001;72:1945-9.
11. Mead J, Folk F. Gastrointestinal bleeding after cardiac surgery. N Engl J Med 1969;281:799.
12. Driks MR, Craven DE, Celli BR, Manning M, Burke RA, Garvin GM et al. Nosocomial pneumonia in intubated patients given sucralfate as compared with antacids or histamine type 2 blockers. The role of gastric colonisation. N Engl J Med 1987;317:1376-82.
13. Tryba M. Risk of acute stress bleeding and nosocomial pneumonia in ventilated intensive care unit patients: sucralfate versus antacids. Am J Med 1987;83:117-24.
14. Eom CS, Jeon CY, Lim JW, Cho EG, Park SM, Lee KS. Use of acidsuppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ 2011;183:310-9.
15. Juurlink DN, Gomes T, Ko DT, Szmitko PE, Austin PC, Tu JV et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009;180:713-8.
16. Dunn SP, Macaulay TE, Brennan DM, Campbell CL, Charnigo RJ, Smyth SS et al. Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO Trial (abstract 3999). Circulation 2008;118: 815.
17. O'Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009;374:989-97.